Dong Ho Lee

Dong Ho Lee

Auto-generated profile, based on publicly available information

Dong Ho Lee

Bio & Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RARaghavendra Achary
Raghavendra Achary
GMGangadhar Rao Mathi
Gangadhar Rao Mathi
DLDong Ho Lee
Dong Ho Lee
CYChang Soo Yun
Chang Soo Yun
CLChong Ock Lee
Chong Ock Lee
JHJong Yeon Hwang
Jong Yeon Hwang

9 November 2017 in Molecules
Verified
Journal Article
Open access
PDF file
DLDong-Ho Lee
Dong-Ho Lee
JLJoo-Youn Lee
Joo-Youn Lee
JJJieun Jeong
Jieun Jeong
MKMiok Kim
Miok Kim
KLKyung Won Lee
Kyung Won Lee
JHJong Yeon Hwang
Jong Yeon Hwang
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme that is highly overexpressed in various cancer cells and antigen-presenting cells. It has emerged as an attractive therapeutic target for cancer immunotherapy, which has prompted high interest in the development of small-molecule inhibitors. To discover novel IDO1 inhibitors, we designed and synthesized a series of N′-hydroxyindazolecarboximidamides. Among the compounds synthesized, compound 8a inhibited both tryptophan depletion and kynurenine production through the IDO1 enzyme. Molecular docking studies revealed that 8a binds to IDO1 with the same binding mode as the analog, epacadostat (INCB24360). Here, we report the synthesis and biological evaluation of these hydroxyindazolecarboximidamides and present the molecular docking study of 8a with IDO1.